MBX Biosciences, Inc. Common Stock (MBX) Stock Forecast & Price Target
MBX Biosciences, Inc. Common Stock · NASDAQ
$60.00-1.30 (-2.12%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering MBX Biosciences, Inc. Common Stock, 10 rate it Buy or better, 0 sit at Hold, and 1 rate it Sell or worse, a strong buy consensus. The target range is very wide, $18.00 to $88.00 (about 4.9x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $61.40 sits 2% above the current $60.00. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 9 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.72 next quarter toward $-3.60 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Strong Buy
Strong Buy00%
Buy1091%
Hold00%
Sell19%
Strong Sell00%
Based on 11 analysts giving stock ratings to MBX Biosciences, Inc. Common Stock.
As of Jul, 10 of 11 firms rate MBX a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
MBX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.72
Range $-0.87 – $-0.60 · 7 analysts · +15% YoY
Next period, 7 analysts expect MBX Biosciences, Inc. Common Stock to earn $-0.72 a share (range $-0.87 – $-0.60), versus $-0.63 a year earlier. Full-year consensus is $-2.71, growing to $-3.60 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering MBX Biosciences, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MBX.
#1
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$86.00+43.3% to target
Overall win rate
44%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #64
Buy
No targeton MBX
Overall win rate
52%
+ Follow
#3
Seamus Fernandez
Guggenheim
Buy
$88.00+46.7% to target
Coverage
—
+ Follow
#4
UE
Uy Ear
Mizuho
Buy
$57.00-5.0% to target
Coverage
—
+ Follow
#5
Eliana Merle
Barclays
Buy
$70.00+16.7% to target
Coverage
—
+ Follow
MBX stock forecast FAQ
What is MBX's average 12-month price target?+
The 10 analysts with a live target average $61.40 for MBX Biosciences, Inc. Common Stock over the next 12 months, ranging from a $88.00 high to a $18.00 low.
Is MBX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 11 analyst ratings, 10 are Buy or Strong Buy, 0 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for MBX?+
The Street-high target is $88.00 (Guggenheim), and the Street-low is $18.00 (Goldman Sachs). The average of all 10 active targets is $61.40.
How many Wall Street analysts cover MBX?+
11 analysts have an active rating on MBX Biosciences, Inc. Common Stock, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering MBX?+
Among analysts who currently cover MBX, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #38). Their current call is Buy with a $86.00 target.
What is MBX Biosciences, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.72 per share (range $-0.87 – $-0.60) across 7 analysts. Full-year EPS is projected at $-2.71, rising to $-3.60 the following year.
How much revenue is MBX Biosciences, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading MBX lately?+
As of Jul, 10 of 11 firms rate MBX a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MBX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
